Dr. Arun Sayram Singh, MD

Dr. Singh practices at UCLA Santa Monica Medical Center in Santa Monica, California, part of University of California Health.

Dr. Singh's NPI, 1285817932, was assigned on December 17, 2007. Dr. Singh graduated from Rutgers New Jersey Medical School in 2005. Dr. Singh's California license number on file is A104027.

Dr. Singh's primary practice is UCLA Santa Monica Medical Center, at 1250 16th Street, Santa Monica, CA 90404 in Los Angeles County. The practice phone is (310) 319-4000.

Dr. Singh's primary practice is UCLA Santa Monica Medical Center in Santa Monica, California, part of University of California Health. Dr. Singh is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is UCLA Medical Group. Dmand AI also links Dr. Singh to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Singh practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Singh's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Singh has a license on file in California.

Dmand AI lists breast cancer, chronic anemia, colorectal cancer, lung cancer, lymphoma, multiple myeloma, neutropenia and prostate cancer among the conditions Dr. Singh treats.

CMS data shows 1,553 Medicare services from Dr. Singh across 16 procedure codes in 2024, for 293 Medicare patients. Medicare paid $97,225 for them.

CMS counts 293 Medicare patients who saw Dr. Singh in 2024. The largest group is 65 to 74, with 137 patients. 74% of them have high cholesterol, and 71% have high blood pressure. 17% are also on Medicaid. Their average risk score is 2.33, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Singh's median patient age at 62, with 51% women.

In 2024, Dr. Singh wrote 444 Medicare Part D claims for 79 patients. 77% of them were for generic drugs. CMS names the drug for 237 of them, across 12 drugs with 11 or more claims each, at $1,705,304 in total drug cost. In 2023, CMS named 152 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Singh for performance year 2024, reported as part of a group. Dr. Singh accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Singh as offering telehealth.

Dmand AI links 43 papers to Dr. Singh, published from 2004 to 2025. 2017 was the busiest year, with 9. The most frequent topics are Sarcoma, Prostatic Neoplasms and Biomarkers, Tumor. Dr. Singh has published most often in Clin Cancer Res. Dr. Singh's most frequent co-authors are Bartosz Chmielowski, MD, PhD, Nicholas Matthew Bernthal, MD and Irmina Anna Elliott, MD.

Dmand AI links Dr. Singh to 7 clinical trials, 3 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Gastrointestinal Stromal Tumors, Histiocytoma and Histiocytoma, Malignant Fibrous. Jonsson Comprehensive Cancer Center sponsors the most, 3. Open Payments lists research payments to Dr. Singh that name 2 trials.

CMS Open Payments shows 205 general payments to Dr. Singh from 15 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 38% of the total. Daiichi Sankyo Inc. paid the most, $49,844. It also lists 3 research payments totaling $4,076 from 2016 to 2025, naming 2 clinical trials.

Dr. Singh graduated from Rutgers New Jersey Medical School in 2005.

Dr. Singh is in network with 14 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.